Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain

NCT00227188•Pfizer

Summary

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Eligibility

Age

0 - 5 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
•Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

Locations (1)

Pfizer Investigational Site

Bilbao, Spain

Key Dates

Start Date

May 1, 2003

Primary Completion Date

December 1, 2005

Completion Date

December 1, 2005

Last Updated

November 29, 2012

Enrollment

408

ACTUAL participants

Conditions

Invasive Pneumococcal Disease

Interventions

Pneumococcal 7-valent conjugate vaccine Prevnar

DRUG

An Epidemiological Survey to Establish the Spectrum of Circulating Serotypes of S. Pneumoniae, in Patients Older 18 Years

NCT04464291

Pneumonia, PneumococcalInvasive Pneumococcal Disease+1 more

View study

COMPLETED

Study Estimating the Impact of Prevnar 13™ (13vPnC) on Invasive Pneumococcal Disease

NCT01128439

Invasive Pneumococcal Disease

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 29, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions